恢复 p53 肿瘤抑制因子的活性作为一种抗癌治疗策略。
Restoring p53 tumor suppressor activity as an anticancer therapeutic strategy.
机构信息
University of Arizona, Arizona Cancer Center, 1515 North Campbell Avenue, Tucson, AZ 85724, USA.
出版信息
Future Oncol. 2010 Dec;6(12):1857-62. doi: 10.2217/fon.10.132.
Abstract
Loss of p53 tumor suppressor function is a key event in the genesis of most human tumors. This observation has prompted efforts to restore p53 activity as an anticancer therapeutic approach. Recent developments that have extended our understanding of how p53 activity is regulated and how mutations disrupt that regulation have provided the insight needed to develop therapeutic strategies that take advantage of this knowledge. In this article, we review the strategies for restoring p53 function and some of the new compounds that show promise as antitumor agents in preclinical models.
摘要
抑癌基因 p53 的失活是大多数人类肿瘤发生的关键事件。这一观察结果促使人们努力恢复 p53 的活性，将其作为一种抗癌治疗方法。最近的研究进展加深了我们对 p53 活性如何受到调控以及突变如何破坏这种调控的理解，为开发利用这些知识的治疗策略提供了必要的依据。本文综述了恢复 p53 功能的策略，以及一些在临床前模型中显示出作为抗肿瘤药物潜力的新型化合物。
相似文献
1
Restoring p53 tumor suppressor activity as an anticancer therapeutic strategy.恢复 p53 肿瘤抑制因子的活性作为一种抗癌治疗策略。
Future Oncol. 2010 Dec;6(12):1857-62. doi: 10.2217/fon.10.132.
2
Pharmacological reactivation of p53 as a strategy to treat cancer.作为治疗癌症的策略，药理学激活 p53。
J Intern Med. 2015 Feb;277(2):248-259. doi: 10.1111/joim.12336.
3
Peptide activators of the p53 tumor suppressor.p53 肿瘤抑制因子的肽类激活剂。
Curr Pharm Des. 2011;17(6):603-9. doi: 10.2174/138161211795222577.
4
Restoring p53 function in cancer: novel therapeutic approaches for applying the brakes to tumorigenesis.恢复癌症中的 p53 功能：应用 brakes 抑制肿瘤发生的新治疗方法。
Recent Pat Anticancer Drug Discov. 2010 Jan;5(1):1-13. doi: 10.2174/157489210789702172.
5
Small molecule agents targeting the p53-MDM2 pathway for cancer therapy.针对癌症治疗的 p53-MDM2 通路的小分子药物。
Med Res Rev. 2012 Nov;32(6):1159-96. doi: 10.1002/med.20236. Epub 2011 Jan 16.
6
The role of p53 in cancer drug resistance and targeted chemotherapy.p53在癌症耐药性和靶向化疗中的作用。
Oncotarget. 2017 Jan 31;8(5):8921-8946. doi: 10.18632/oncotarget.13475.
7
MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer.正在临床评估中的 MDM2/X 抑制剂：用于血液系统恶性肿瘤和儿科癌症治疗的前景。
J Hematol Oncol. 2017 Jul 3;10(1):133. doi: 10.1186/s13045-017-0500-5.
8
DIMP53-1: a novel small-molecule dual inhibitor of p53-MDM2/X interactions with multifunctional p53-dependent anticancer properties.DIMP53-1：一种新型小分子双抑制剂，可抑制p53与MDM2/X的相互作用，具有多功能的p53依赖性抗癌特性。
Mol Oncol. 2017 Jun;11(6):612-627. doi: 10.1002/1878-0261.12051. Epub 2017 May 2.
9
MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models.MDM2 小分子拮抗剂 RG7112 激活 p53 信号通路并在临床前癌症模型中使人类肿瘤消退。
Cancer Res. 2013 Apr 15;73(8):2587-97. doi: 10.1158/0008-5472.CAN-12-2807. Epub 2013 Feb 11.
10
MDM2 and MDM4: p53 regulators as targets in anticancer therapy.MDM2与MDM4：作为抗癌治疗靶点的p53调节因子
Int J Biochem Cell Biol. 2007;39(7-8):1476-82. doi: 10.1016/j.biocel.2007.03.022. Epub 2007 Apr 8.
引用本文的文献
1
Waldenström Macroglobulinemia: The Role of TP53 Mutations in Disease Progression and Therapeutic Response.华氏巨球蛋白血症：TP53突变在疾病进展和治疗反应中的作用
Curr Issues Mol Biol. 2025 Apr 8;47(4):260. doi: 10.3390/cimb47040260.
2
Genome Engineering as a Therapeutic Approach in Cancer Therapy: A Comprehensive Review.基因组工程作为癌症治疗的一种治疗方法：全面综述
Adv Genet (Hoboken). 2024 Feb 5;5(1):2300201. doi: 10.1002/ggn2.202300201. eCollection 2024 Mar.
3
The role of p53 in anti-tumor immunity and response to immunotherapy.p53在抗肿瘤免疫及免疫治疗反应中的作用。
Front Mol Biosci. 2023 Aug 1;10:1148389. doi: 10.3389/fmolb.2023.1148389. eCollection 2023.
4
Multiple functions of p21 in cancer radiotherapy.p21 在癌症放射治疗中的多重作用。
J Cancer Res Clin Oncol. 2021 Apr;147(4):987-1006. doi: 10.1007/s00432-021-03529-2. Epub 2021 Feb 5.
5
The Multifaceted p21 (Cip1/Waf1/) in Cell Differentiation, Migration and Cancer Therapy.细胞分化、迁移及癌症治疗中的多面性p21（Cip1/Waf1/）
Cancers (Basel). 2019 Aug 21;11(9):1220. doi: 10.3390/cancers11091220.
6
Wip1 inhibitor GSK2830371 inhibits neuroblastoma growth by inducing Chk2/p53-mediated apoptosis.Wip1 抑制剂 GSK2830371 通过诱导 Chk2/p53 介导的细胞凋亡抑制神经母细胞瘤的生长。
Sci Rep. 2016 Dec 19;6:38011. doi: 10.1038/srep38011.
7
Sensitivity to PRIMA-1MET is associated with decreased MGMT in human glioblastoma cells and glioblastoma stem cells irrespective of p53 status.对PRIMA-1MET的敏感性与人类胶质母细胞瘤细胞和胶质母细胞瘤干细胞中MGMT的减少有关，而与p53状态无关。
Oncotarget. 2016 Sep 13;7(37):60245-60269. doi: 10.18632/oncotarget.11197.
8
Modulation of p53 during bacterial infections.细菌感染过程中 p53 的调节。
Nat Rev Microbiol. 2015 Dec;13(12):741-8. doi: 10.1038/nrmicro3537. Epub 2015 Nov 9.
9
The predictive role of p16 deletion, p53 deletion, and polysomy 9 and 17 in pancreatic ductal adenocarcinoma.p16 缺失、p53 缺失以及 9 号和 17 号染色体三体在胰腺导管腺癌中的预测作用。
Pathol Oncol Res. 2013 Jan;19(1):35-40. doi: 10.1007/s12253-012-9555-3. Epub 2012 Jul 11.
10
A journey under the sea: the quest for marine anti-cancer alkaloids.海洋抗癌生物碱的追寻之旅
Molecules. 2011 Nov 23;16(11):9665-96. doi: 10.3390/molecules16119665.
本文引用的文献
1
Mdm2-mediated ubiquitylation: p53 and beyond.Mdm2 介导的泛素化：p53 及其他。
Cell Death Differ. 2010 Jan;17(1):93-102. doi: 10.1038/cdd.2009.68.
2
PRIMA-1 reactivates mutant p53 by covalent binding to the core domain.PRIMA-1通过与核心结构域共价结合来重新激活突变型p53。
Cancer Cell. 2009 May 5;15(5):376-88. doi: 10.1016/j.ccr.2009.03.003.
3
The genetics of the p53 pathway, apoptosis and cancer therapy.p53信号通路、细胞凋亡与癌症治疗的遗传学
Nat Rev Drug Discov. 2008 Dec;7(12):979-87. doi: 10.1038/nrd2656.
4
The p53 family and programmed cell death.p53家族与程序性细胞死亡
Oncogene. 2008 Oct 27;27(50):6507-21. doi: 10.1038/onc.2008.315.
5
Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition.一种特定的MDM2抑制剂对p53的短暂激活对肿瘤具有选择性毒性，并导致肿瘤生长完全抑制。
Proc Natl Acad Sci U S A. 2008 Mar 11;105(10):3933-8. doi: 10.1073/pnas.0708917105. Epub 2008 Mar 3.
6
Biochemical and structural studies of ASPP proteins reveal differential binding to p53, p63, and p73.ASPP蛋白的生化与结构研究揭示了其与p53、p63和p73的差异结合。
Structure. 2008 Feb;16(2):259-68. doi: 10.1016/j.str.2007.11.012.
7
ATM and the Mre11 complex combine to recognize and signal DNA double-strand breaks.共济失调毛细血管扩张症突变基因（ATM）与Mre11复合物共同作用，以识别DNA双链断裂并发出信号。
Oncogene. 2007 Dec 10;26(56):7749-58. doi: 10.1038/sj.onc.1210880.
8
Synergistic cytotoxic activity of recombinant TRAIL plus the non-genotoxic activator of the p53 pathway nutlin-3 in acute myeloid leukemia cells.重组肿瘤坏死因子相关凋亡诱导配体（TRAIL）与p53通路的非基因毒性激活剂Nutlin-3联合作用对急性髓系白血病细胞的协同细胞毒性活性。
Curr Drug Metab. 2007 May;8(4):395-403. doi: 10.2174/138920007780655432.
9
Structure-function-rescue: the diverse nature of common p53 cancer mutants.结构-功能挽救：常见p53癌症突变体的多样性质
Oncogene. 2007 Apr 2;26(15):2226-42. doi: 10.1038/sj.onc.1210291.
10
INGN 201 (Advexin): adenoviral p53 gene therapy for cancer.INGN 201（艾达生）：用于癌症治疗的腺病毒p53基因疗法。
Expert Opin Biol Ther. 2006 Aug;6(8):823-32. doi: 10.1517/14712598.6.8.823.
Zotero 插件